Chemistry:Pibrentasvir
From HandWiki
Short description: NS5A inhibitor antiviral agent
Clinical data | |
---|---|
Trade names | Mavyret, Maviret (combination with glecaprevir) |
Other names | ABT-530 |
Pharmacokinetic data | |
Protein binding | >99.9% |
Elimination half-life | 13 hours |
Excretion | 96.6% in faeces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C57H65F5N10O8 |
Molar mass | 1113.201 g·mol−1 |
3D model (JSmol) | |
| |
|
Pibrentasvir is an NS5A inhibitor antiviral agent.[1] In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C.[2][3] It is sold by Abbvie.[citation needed]
References
- ↑ "In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir". Antimicrobial Agents and Chemotherapy 61 (5): e02558–16. May 2017. doi:10.1128/AAC.02558-16. PMID 28193664.
- ↑ "FDA OKs new drug to treat all forms of hepatitis C". Fox Business. August 3, 2017. http://www.foxbusiness.com/markets/2017/08/03/fda-oks-new-drug-to-treat-all-forms-hepatitis-c.html.
- ↑ "Maviret: EPAR – Summary for the public". European Medicines Agency. 2017-08-17. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004430/WC500233680.pdf.
Original source: https://en.wikipedia.org/wiki/Pibrentasvir.
Read more |